Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
ApexOnco Front Page
Recent articles
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
The response rate jumps to 30% with higher doses of IMA402.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
